Newly released data shows that the U.S. may have reached peak obesity in 2020 — and the timing unsurprisingly coincides with ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

Discover how new weight loss drugs from Novo Nordisk (NVO) and Eli Lilly (LLY) may have helped reduce U.S. obesity rates.

Medicare is prohibited by law from covering GLP-1 drugs for weight loss. But many beneficiaries can access the drugs anyway.

Most telling though, the results that show that the overall obesity rate in the U.S. has not changed significantly in a ...

The U.S. obesity rate is about 40%, according to a 2021-2023 survey ... s too soon to know whether new treatments for obesity, including blockbuster weight-loss drugs such as Wegovy and Zepbound ...

The U.S. obesity rate is about 40 percent, according to a 2021-2023 survey of about ... WATCH: The many ways new weight loss drugs could transform the economy The overall obesity rate appeared ...

An obesity expert weighs in on intriguing new data and new drugs that hold promise in the battle against a stubborn problem.

The U.S. obesity rate is about 40%, according to a 2021-2023 survey ... s too soon to know whether new treatments for obesity, including blockbuster weight-loss drugs such as Wegovy and Zepbound ...

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

Dr. Eileen Barr, an obesity physician in East Setauket, said the new drugs are being released at ... found that New York's obesity rate rose from 29.1% in 2021 to 30.1% in 2022 before falling ...